Literature DB >> 29336783

Bronchiectasis is highly prevalent in anti-MPO ANCA-associated vasculitis and is associated with a distinct disease presentation.

Antoine Néel1, Alexandra Espitia-Thibault2, Pierre-Paul Arrigoni3, Christelle Volteau4, Marie Rimbert5, Agathe Masseau2, Christian Agard2, Fadi Fakhouri6, Renan Liberge3, Mohamed Hamidou7.   

Abstract

OBJECTIVES: To assess the prevalence of bronchiectasis in a Western cohort with ANCA-positive granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) and its correlations with disease presentation and outcome.
METHODS: Retrospective study of ANCA-associated vasculitis (AAV) patients followed at Nantes University Hospital (2005-2015). Clinical, biological, and follow-up data were collected through chart review. Two experienced radiologists blinded to the clinical data interpreted chest high-resolution CTs according to the Feischner Society criteria.
RESULTS: Fifty-eight patients were included: 30 had MPA (51.7%) and 28 had GPA (48.3%). The median age at AAV diagnosis was 65.5 years. Anti-MPO-ANCA and anti-PR3-ANCA were present in 39 (67.2%) and 19 (32.8%) patients, respectively. Overall, bronchiectasis was found in 22 patients (37.9%), all of whom had anti-MPO ANCA. In multivariate analysis, bronchiectasis was independently associated with anti-MPO-ANCA, female gender and age at AAV diagnosis. Furthermore, anti-MPO ANCA patients with bronchiectasis had more frequent peripheral nerve involvement (54.5 vs. 17.6%, p = 0.019) and less frequent renal involvement than those without bronchiectasis (40.9% vs. 82.3%, p = 0.009). Disease course, survival and risk of severe pulmonary infection were similar in patients with and without bronchiectasis on chest CT.
CONCLUSIONS: This study shows that bronchiectasis is a highly prevalent pre-existing respiratory condition in Caucasian patients with anti-MPO AAV. This subset of patients exhibits a distinct presentation. Further studies are needed to confirm these findings and clarify the clinical implications of this association. Whether the respiratory tract could be the site of initiation of anti-MPO auto-immunity remains to be investigated.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ANCA-associated vasculitis; Anti-MPO; Bronchiectasis; Interstitial lung disease; Microscopic polyangiitis

Mesh:

Substances:

Year:  2017        PMID: 29336783     DOI: 10.1016/j.semarthrit.2017.12.002

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  7 in total

Review 1.  Pathogenesis of ANCA-Associated Pulmonary Vasculitis.

Authors:  Marco A Alba; J Charles Jennette; Ronald J Falk
Journal:  Semin Respir Crit Care Med       Date:  2018-11-07       Impact factor: 3.119

2.  Patterns of lung diseases predict survival in patients with MPO-ANCA-associated vasculitis: a single-center retrospective study.

Authors:  Shuqiao Yang; Dandan Chai; Yihua Li; Yuanying Wang; Xi Zhan; Liming Zhang; Jing Wang; Qiao Ye
Journal:  Clin Rheumatol       Date:  2021-11-27       Impact factor: 2.980

3.  Association of Cigarette Smoking With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

Authors:  Greg McDermott; Xiaoqing Fu; John H Stone; Rachel Wallwork; Yuqing Zhang; Hyon K Choi; Zachary S Wallace
Journal:  JAMA Intern Med       Date:  2020-06-01       Impact factor: 21.873

4.  Novel insights into the aetiology of granulomatosis with polyangiitis-a case-control study using the Clinical Practice Research Datalink.

Authors:  Fiona A Pearce; Peter C Lanyon; Richard A Watts; Matthew J Grainge; Abhishek Abhishek; Richard B Hubbard
Journal:  Rheumatology (Oxford)       Date:  2018-06-01       Impact factor: 7.580

5.  Pulmonary involvement of ANCA-associated vasculitis in adult Chinese patients.

Authors:  Peining Zhou; Zhiying Li; Li Gao; Chengli Que; Haichao Li; Jing Ma; Guangfa Wang; Min Chen
Journal:  BMC Pulm Med       Date:  2022-01-12       Impact factor: 3.317

Review 6.  ANCA Associated Vasculitis Subtypes: Recent Insights and Future Perspectives.

Authors:  Keziah Austin; Shalini Janagan; Matthew Wells; Helena Crawshaw; Stephen McAdoo; Joanna C Robson
Journal:  J Inflamm Res       Date:  2022-04-21

Review 7.  Personalized Medicine in ANCA-Associated Vasculitis ANCA Specificity as the Guide?

Authors:  Zachary S Wallace; John H Stone
Journal:  Front Immunol       Date:  2019-12-06       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.